Autopsy report · NCT03221166

Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

“Difficulty in recruiting subjects who meet the inclusion/exclusion criteria”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 2 years 5 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

IRCCS Burlo Garofolo

Sponsor type

University, hospital or other

Conditions

Crohn Disease

Interventions

Thalidomide; Infliximab

Participants

9

Sites

6

Countries

Italy

Trials that died the same way

• Dilantin Levels With Continuous Delivery of Enteral Feedings - A Pilot Study
  “Difficulty recruiting subjects” (80% match in meaning)
• Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
  “Difficulty in identifying subjects satisfying the inclusion criteria.” (77% match in meaning)
• The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives
  “Inability to recruit eligible subjects” (76% match in meaning)
• Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
  “Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.” (75% match in meaning)
• Effects of Psilocybin in Concussion Headache
  “Challenging to recruit qualifying subjects” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.